Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 7 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 6 | 5 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $336.2, a high estimate of $400.00, and a low estimate of $296.00. This current average has increased by 2.93% from the previous average price target of $326.64.
Investigating Analyst Ratings: An Elaborate Study
In examining recent analyst actions, we gain insights into how financial experts perceive Alnylam Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joseph Stringer | Needham | Maintains | Buy | $320.00 | $320.00 |
| William Pickering | Bernstein | Lowers | Outperform | $310.00 | $314.00 |
| Edward Tenthoff | Piper Sandler | Maintains | Overweight | $296.00 | $296.00 |
| Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $400.00 | $400.00 |
| Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $400.00 | $400.00 |
| Gary Nachman | Raymond James | Raises | Outperform | $298.00 | $275.00 |
| Luca Issi | RBC Capital | Maintains | Outperform | $300.00 | $300.00 |
| Greg Harrison | Scotiabank | Raises | Sector Outperform | $310.00 | $305.00 |
| Gena Wang | Barclays | Raises | Overweight | $329.00 | $295.00 |
| Whitney Ijem | Canaccord Genuity | Raises | Buy | $384.00 | $366.00 |
| Keay Nakae | Chardan Capital | Maintains | Buy | $300.00 | $300.00 |
| Joseph Stringer | Needham | Maintains | Buy | $320.00 | $320.00 |
| Ritu Baral | TD Cowen | Raises | Buy | $371.00 | $282.00 |
| Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $400.00 | $400.00 |
| Greg Harrison | Scotiabank | Announces | Sector Outperform | $305.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alnylam Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Alnylam Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Alnylam Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Alnylam Pharmaceuticals analyst ratings.
Unveiling the Story Behind Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
A Deep Dive into Alnylam Pharmaceuticals's Financials
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Alnylam Pharmaceuticals faced challenges, resulting in a decline of approximately -33.26% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Alnylam Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -22.27%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -761.91%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.72%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Alnylam Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 40.24. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
The Significance of Analyst Ratings Explained
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
